The pharmacological giant Sun Pharma has joined hands with International Centre for Genetic Engineering and Biotechnology (ICGEB) for the development of a botanical drug, plant-based drug, for the treatment of dengue. The agreement mentions that Sun Pharma will help in the development of Cissampelos pariera (Cipa), a botanical drug following a drug registration process meeting regularity standards of India and world. ICGEB will work exclusively with Sun Pharma for the development of the drug and clinical treatment strategies based on botanical and phyto-pharmaceuticals. Sun Pharma will conduct a scientific evaluation of the safety and efficacy of the drug along with building a strong intellectual property base for commercialization of the botanical drug. Also read about 33 FAQs about dengue answered.
Dengue treatment what do you need to know?
Most people are unaware of the fact that there is no specific drug to treat dengue as of now. The patients suffering from this parasitic infection are treated for the symptoms and fight infection caused by the virus. As low platelet count characterizes the condition, treatment option usually involves increasing the platelet and this is the same for all symptoms. Additionally, it involves taking medications and maintaining fluid-electrolyte balance in the body. Here s more on is there a specific treatment for dengue? Our experts tell you.
What do the researchers have to say?
According to Dr Dinakar M. Salunke, Director International Centre for Genetic Engineering and Biotechnology, New Delhi, Dengue, a mosquito-borne viral disease, poses a significant global public health risk. In tropical countries such as India where periodic dengue outbreaks can be correlated to the high prevalence of the mosquito vector, circulation of all four dengue viruses (DENVs) and the high population density, a drug for dengue is being increasingly recognized as an unmet public health need. Using the knowledge of traditional Indian medicine, we explored the indigenous herbal bio-resource to identify plants with pan-DENV inhibitory activity and identified CIPA as a safe, affordable and efficient solution.
Commenting on the company s partnership with ICGEB, Mr Kirti Ganorkar, Senior Vice President Business Development & Portfolio Management, Sun Pharma said, Dengue poses a significant global public health risk. In tropical countries like India where dengue outbreaks are significantly intense, a drug for dengue is recognised as an unmet public health need. Our partnership with ICGEB aims to develop Cipa as a safe, effective & affordable botanical drug for treatment of dengue.
How will this medication help?
According to statistics, 50% of the global population at risk of dengue are Indians. If left untreated, dengue might lead to high viral load, a severe reduction in platelets and brain haemorrhage, ultimately leading to death. The antiviral therapies which are currently used help in attenuating the disease severity. However, the new drug aims at inhibiting the replication of the dengue virus in living cells thereby treating the condition. Also read about 10 practical tips to be mosquito-free and prevent dengue!
Source: Press Release/Sun Pharma
Image Source: Shutterstock
